Keros Therapeutics Q3 GAAP EPS $0.70 vs $(0.18) YoY, Includes $40.0M Takeda License Revenue; Revenue $40.01M vs $14.26M YoY
Share
Why It Matters
Keros made more money this quarter than last year. One big reason was a special payment from another company, so watch if regular business is growing too.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.